FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938562767> ?p ?o ?g. }

• W2938562767 endingPage "2787" @default.
• W2938562767 startingPage "2777" @default.
• W2938562767 abstract "Aims: Pyrotinib is a newly developed irreversible pan-ErbB receptor tyrosine kinase inhibitor for treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, and clinic trials of pyrotinib in treatment of HER2-positive gastric cancer (GC) are underway. Exosomes are tiny vesicles secreted by cancer cells and take essential roles in the progression of carcinoma. Whether pyrotinib application has any effect on the cancer cell-released exosomes has not been studied. The aim of our work was to address if pyrotinib treatment impacts the effect of HER2-positive GC cell-derived exosomes on endothelial cell (EC) progression. Methods: Isolation of exosomes released by HER2-positive NCI-N87 and MKN45 lines after pyrotinib treatment was performed. Then, human umbilical vein endothelial cells (HUVECs) were incubated with different concentrations of exosomes to address their proliferation by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS). Effect of pyrotinib-treated exosomes at concentration of 10 µg/mL was compared to that without pyrotinib treatment over 96-hr time course. Transwell assay and wound-healing assay were carried out by incubating with exosomes released by NCI-N87 and MKN45 cells with/without pyrotinib treatment over 24-hr time course. The aforementioned experiments were done under same conditions in order to evaluate the combined effect of apatinib and pyrotinib on HUVEC motility and invasive capacity. Results: We showed that HUVEC proliferation, motility and invasive capacity were further enhanced upon incubation with exosomes released by pyrotinib-treated GC cell lines, compared to those without pyrotinib treatment. Significantly, this effect was counteracted by the vascular endothelial growth factor receptor (VEGFR)-2 inhibitor apatinib which inhibits EC progression. Conclusion: Our study suggests that pyrotinib application on HER2-positive GC produces stronger exosomes that promote the proliferation and motility of vascular ECs, and combination of pyrotinib with apatinib provides potentially better therapy." @default.
• W2938562767 created "2019-04-25" @default.
• W2938562767 creator A5007278822 @default.
• W2938562767 creator A5029547026 @default.
• W2938562767 creator A5029576882 @default.
• W2938562767 creator A5047693269 @default.
• W2938562767 creator A5054260188 @default.
• W2938562767 creator A5077812851 @default.
• W2938562767 creator A5089843079 @default.
• W2938562767 date "2019-04-01" @default.
• W2938562767 modified "2023-10-09" @default.
• W2938562767 title "<p>Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib</p>" @default.
• W2938562767 cites W1553254670 @default.
• W2938562767 cites W1985576417 @default.
• W2938562767 cites W2016884538 @default.
• W2938562767 cites W2024651005 @default.
• W2938562767 cites W2042751187 @default.
• W2938562767 cites W2078454159 @default.
• W2938562767 cites W2088145034 @default.
• W2938562767 cites W2096111541 @default.
• W2938562767 cites W2114282952 @default.
• W2938562767 cites W2145092426 @default.
• W2938562767 cites W2150654884 @default.
• W2938562767 cites W2154027407 @default.
• W2938562767 cites W2161692381 @default.
• W2938562767 cites W2184959883 @default.
• W2938562767 cites W2213890440 @default.
• W2938562767 cites W2403293254 @default.
• W2938562767 cites W2567639438 @default.
• W2938562767 cites W2577651608 @default.
• W2938562767 cites W2604542034 @default.
• W2938562767 cites W2607037368 @default.
• W2938562767 cites W2613098450 @default.
• W2938562767 cites W2738491178 @default.
• W2938562767 cites W2771694251 @default.
• W2938562767 cites W2802208937 @default.
• W2938562767 cites W2805516250 @default.
• W2938562767 cites W2896327236 @default.
• W2938562767 cites W2897683782 @default.
• W2938562767 cites W2898271338 @default.
• W2938562767 doi "https://doi.org/10.2147/ott.s194768" @default.
• W2938562767 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6489591" @default.
• W2938562767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31114227" @default.
• W2938562767 hasPublicationYear "2019" @default.
• W2938562767 type Work @default.
• W2938562767 sameAs 2938562767 @default.
• W2938562767 citedByCount "15" @default.
• W2938562767 countsByYear W29385627672020 @default.
• W2938562767 countsByYear W29385627672021 @default.
• W2938562767 countsByYear W29385627672022 @default.
• W2938562767 crossrefType "journal-article" @default.
• W2938562767 hasAuthorship W2938562767A5007278822 @default.
• W2938562767 hasAuthorship W2938562767A5029547026 @default.
• W2938562767 hasAuthorship W2938562767A5029576882 @default.
• W2938562767 hasAuthorship W2938562767A5047693269 @default.
• W2938562767 hasAuthorship W2938562767A5054260188 @default.
• W2938562767 hasAuthorship W2938562767A5077812851 @default.
• W2938562767 hasAuthorship W2938562767A5089843079 @default.
• W2938562767 hasBestOaLocation W29385627671 @default.
• W2938562767 hasConcept C104317684 @default.
• W2938562767 hasConcept C121608353 @default.
• W2938562767 hasConcept C126322002 @default.
• W2938562767 hasConcept C145059251 @default.
• W2938562767 hasConcept C1491633281 @default.
• W2938562767 hasConcept C185592680 @default.
• W2938562767 hasConcept C202751555 @default.
• W2938562767 hasConcept C20518536 @default.
• W2938562767 hasConcept C2777411675 @default.
• W2938562767 hasConcept C2778877718 @default.
• W2938562767 hasConcept C2779306644 @default.
• W2938562767 hasConcept C2780323712 @default.
• W2938562767 hasConcept C2780668389 @default.
• W2938562767 hasConcept C502942594 @default.
• W2938562767 hasConcept C55493867 @default.
• W2938562767 hasConcept C58207958 @default.
• W2938562767 hasConcept C62112901 @default.
• W2938562767 hasConcept C71924100 @default.
• W2938562767 hasConcept C86803240 @default.
• W2938562767 hasConcept C95444343 @default.
• W2938562767 hasConcept C96232424 @default.
• W2938562767 hasConcept C98274493 @default.
• W2938562767 hasConceptScore W2938562767C104317684 @default.
• W2938562767 hasConceptScore W2938562767C121608353 @default.
• W2938562767 hasConceptScore W2938562767C126322002 @default.
• W2938562767 hasConceptScore W2938562767C145059251 @default.
• W2938562767 hasConceptScore W2938562767C1491633281 @default.
• W2938562767 hasConceptScore W2938562767C185592680 @default.
• W2938562767 hasConceptScore W2938562767C202751555 @default.
• W2938562767 hasConceptScore W2938562767C20518536 @default.
• W2938562767 hasConceptScore W2938562767C2777411675 @default.
• W2938562767 hasConceptScore W2938562767C2778877718 @default.
• W2938562767 hasConceptScore W2938562767C2779306644 @default.
• W2938562767 hasConceptScore W2938562767C2780323712 @default.
• W2938562767 hasConceptScore W2938562767C2780668389 @default.
• W2938562767 hasConceptScore W2938562767C502942594 @default.
• W2938562767 hasConceptScore W2938562767C55493867 @default.
• W2938562767 hasConceptScore W2938562767C58207958 @default.
• W2938562767 hasConceptScore W2938562767C62112901 @default.

• next